Donald Decoy, MD
Pulmonary Disease · Canton, OHNPI 1427075191
Payments from drug & device makers
Across 17 payments — averaging $62.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$489
- Harmony Biosciences LLC$151
- United Therapeutics Corporation$116
- Inspire Medical Systems, Inc.$107
- Mylan Specialty L.p.$86
- Boehringer Ingelheim$58
- plus $61 from 3 others
What the payments were for
- Food & beverage$41439%
- Education$65561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 5 | $489 |
| Harmony Biosciences LLC | 2 | $151 |
| United Therapeutics Corporation | 2 | $116 |
| Inspire Medical Systems, Inc. | 2 | $107 |
| Mylan Specialty L.p. | 1 | $86 |
| Boehringer Ingelheim | 2 | $58 |
| Fisher & Paykel Healthcare Inc | 1 | $34 |
| GSK | 1 | $16 |
| Baxter Healthcare | 1 | $12 |
How this compares
$1,069 in reported general payments places this provider in the 40th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 12 | $51,403 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $37,064 |
| Spiriva RespimatTiotropium Bromide | 35 | $28,219 |
| Spiriva HandihalerTiotropium Bromide | 28 | $26,295 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $18,179 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $14,794 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $13,672 |
| Tiotropium Bromide | 13 | $10,734 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 87 | $9,478 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 41 | $9,131 |
| HorizantGabapentin Enacarbil | 12 | $6,007 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,213 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,771 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 139 | $4,312 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $2,848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Incruse Ellipta, Breo Ellipta | $16 | $121,441122 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $58 | $33,43146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Canton
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Leslie TolleCleveland$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.